Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for gastric cancers

ESMO 2021: Latest in EGFR mutated advanced NSCLC

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer

ESMO 2021: PARPi data and their role in mono/combination therapies

Radioembolisation with chemotherapy for colorectal liver metastases

Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

ESMO 2021: Breast cancer roundup

[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer

Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer

Drug combination shows promise in treatment-resistant advanced ovarian cancer

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

ESMO 2021 Roundup

OncoAlert and ecancer - ESMO 2021 Day 5

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation

Anti-cancer drug price regulation in India: Financial implications and annual savings to patients

Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer

OncoAlert and ecancer - ESMO 2021 Day 4

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer

OncoAlert and ecancer - ESMO 2021 Day 3

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

Cabozantinib in combination with atezolizumab in patients with mCRPC

OncoAlert and ecancer - ESMO 2021 Day 2

Long-term outcomes and complications in cancer patients who have recovered from COVID-19

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa

ESMO President: What to watch for at ESMO 2021

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma

OncoAlert and ecancer - ESMO 2021 preview